🧭Clinical Trial Compass

Am I eligible?Pricing About

Clinical Trial Compass

Data sourced from ClinicalTrials.gov and OpenFDA. For informational purposes only. Always consult your healthcare provider.

Not medical advice.

Platelet Agregation in Patients on ECMO (NCT05542134) | Clinical Trial Compass

UnknownNot Applicable

Platelet Agregation in Patients on ECMO

Slovenia50 participantsStarted 2019-01-17

Plain-language summary

An observational study in which investigators will observe platelet inhibition in patients on VA ECMO acorrding to treatment with P2Y12 inhibitor.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * all patients on VA ECMO Exclusion Criteria: * known P2Y12 alergy * thrombocitopenic patents (\< 50\*109/L), * patients treated with eptifibatide ali bivalirudin * patients younger than 18 years * pregnant patients

What they're measuring

1

Verify now P2Y12 platelet inhibition

Timeframe: (Time Frame: Hour 2 after VA ECMO insertion)

2

Verify now P2Y12 platelet inhibition

Timeframe: (Time Frame: Hour 4 after VA ECMO insertion)

3

Verify now P2Y12 platelet inhibition

Timeframe: (Time Frame: Hour 12 after VA ECMO insertion)

4

Verify now P2Y12 platelet inhibition

Timeframe: (Time Frame: Hour 22 after VA ECMO insertion)

5

Verify now P2Y12 platelet inhibition

Timeframe: (Time Frame: Hour 48 after VA ECMO insertion)

6

Verify now P2Y12 platelet inhibition

Timeframe: (Time Frame: Hour 72 after VA ECMO insertion)

7

Verify now P2Y12 platelet inhibition

Timeframe: (Time Frame: Hour 24 after VA ECMO removal)

Trial details

NCT IDNCT05542134

SponsorUniversity Medical Centre Ljubljana

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-06-01

Contact for this trial

Marko Noc, MD, phD

+38641723807 marko.noc@kclj.si

View on ClinicalTrials.gov More Platelet Refractoriness trials